There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bio-Path Holdings (BPTH – Research Report), Argenx Se (ARGX – Research Report) and Revolution Medicines (RVMD – Research Report) with bullish sentiments.
Bio-Path Holdings (BPTH)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bio-Path Holdings today and set a price target of $9.00. The company’s shares closed last Wednesday at $1.44, close to its 52-week low of $1.28.
According to TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Bio-Path Holdings is a Moderate Buy with an average price target of $9.00.
See Insiders’ Hot Stocks on TipRanks >>
Argenx Se (ARGX)
H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Argenx Se today and set a price target of $440.00. The company’s shares closed last Wednesday at $384.37, close to its 52-week high of $407.93.
According to TipRanks.com, Tsao is a 4-star analyst with an average return of
Argenx Se has an analyst consensus of Strong Buy, with a price target consensus of $442.25, implying a 12.7% upside from current levels. In a report issued on December 6, William Blair also initiated coverage with a Buy rating on the stock.
Revolution Medicines (RVMD)
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Revolution Medicines, with a price target of $32.00. The company’s shares closed last Wednesday at $24.15.
According to TipRanks.com, Burns has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revolution Medicines with a $30.67 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BPTH:
- Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
- Bio-Path Holdings Reports Third Quarter 2022 Financial Results
- Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients